$28.34
-0.88-3.02%
At close: -
$31.26
2.9210.30%
After Hours: Sep 19, 8:15 AM EDT
Comments
Loading...
Latest Ipsen Stock News | OTC:IPSEY | Benzinga
Get the latest news on Ipsen stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Ipsen performance
Categories: All
Thursday, October 03, 2024
Thursday, July 25, 2024
Tuesday, June 11, 2024
Monday, June 10, 2024
Monday, April 22, 2024
Tuesday, April 02, 2024
Wednesday, March 27, 2024
Tuesday, February 13, 2024
Thursday, December 07, 2023
Monday, August 21, 2023
Friday, June 30, 2023
Monday, May 22, 2023
Monday, January 09, 2023
Wednesday, December 14, 2022
Friday, December 09, 2022
Wednesday, November 09, 2022
- Why Merrimack Shares Are Surging Over 200% Today?
- Shares of Merrimack Pharmaceuticals Rise 100%...
- Ipsen Announced Onivyde Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma; Trial Met its Primary Endpoint and Key Secondary Endpoint
Tuesday, November 01, 2022
Sunday, October 02, 2022
Monday, September 19, 2022
Wednesday, August 03, 2022
Tuesday, June 28, 2022
Monday, June 27, 2022
- Why Is NeuroSense Therapeutics Surging By 70%? 46 Stocks Moving In Monday's Mid-Day Session
- The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies
- Ipsen Scoops Up Blood Cancer-Focused Epizyme - Read Why
- Ipsen to Acquire Epizyme for $1.45/Share in Cash, Plus a Contingent Value Right of $1.00/Share
Tuesday, May 03, 2022
Friday, March 25, 2022
Tuesday, March 15, 2022
Monday, January 24, 2022
Friday, December 17, 2021
- Genfit Shares Rally After Ipsen Buys Rights To Its Late-Stage Kidney Disease Treatment Hopeful
- Ipsen and GENFIT Announced Exclusive Licensing Agreement for Elafibranor; GENFIT Receives €120M Upfront, Up to €360M in Milestone Payments Plus Royalties of up to 20%; Ipsen Becomes 8% Shareholder of GENFIT
Friday, August 13, 2021
Monday, August 02, 2021
Thursday, July 15, 2021
Monday, June 28, 2021
- Exelixis Shares Drop On Mixed Results For Cabometyx Combo In Early Liver Cancer
- Exelixis and Ipsen Announced Cabozantinib in Combination with an Immune Checkpoint Inhibitor Significantly Improved Progression-Free Survival in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previously Untreated Advanced Liver Cancer